View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ackermans & van Haaren: Results capping already strong subsidiary reporting. DPS beat. Fagron: Acquisition of Pharmavit Europe, active in nutraceutical raw materials. Fugro: Patience please. Kendrion: Sees signs of improvement in EU economy. Proximus: 2026 dividend halved, 2028-30 targets a bit better on lower capex. Proximus: 4Q25 in line EBITDA on weaker sales, FCF up; 2026 guidance below on EBITDA. Recticel: Strong FY25 results, CEO transition seen as a negative

Guy Sips ... (+7)
  • Guy Sips
  • Hilde Van Boxstael
  • Livio Luyten
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Wim Hoste
  • Wim Lewi

Morning Notes : ACKB BB, FAGR BB, FUR NA, MTLS US, MDXH BB, PROX BB, R...

: ACKB BB, FAGR BB, FUR NA, MTLS US, MDXH BB, PROX BB, RECT BB, WHATS BB

 PRESS RELEASE

Fagron completes strategic acquisition of Pharmavit Europe, strengthen...

Fagron completes strategic acquisition of Pharmavit Europe, strengthening its leadership in high‑growth nutraceutical ingredients across EMEA Regulated information – inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 February 2026 – 6:30PM Fagron completes strategic acquisition of Pharmavit Europe, strengthening its leadership in high‑growth nutraceutical ingredients across EMEA Fagron, the leading global player in pharmaceutical compounding, announces that it has completed the acquisition of Pharmavit Europe, a leading European distributor of nutraceutical raw material...

 PRESS RELEASE

Fagron voltooit strategische overname van Pharmavit Europe en versterk...

Fagron voltooit strategische overname van Pharmavit Europe en versterkt daarmee haar leiderschap in snelgroeiende nutraceutische ingrediënten in EMEA Gereglementeerde informatie - voorwetenschapNazareth (België)/Rotterdam (Nederland), 26 februari 2026 – 18:30 Fagron voltooit strategische overname van Pharmavit Europe en versterkt daarmee haar leiderschap in snelgroeiende nutraceutische ingrediënten in EMEA Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, kondigt de afronding aan van de overname van Pharmavit Europe, een toonaangevende Europese distributeur van ...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Aalberts: In-line FY25, but low quality / AMG: 4Q25 beat by 7%; in-line 2026 guidance / Bekaert: In-line 2025, cautious outlook for 2026 to result in c.8% consensus cut / CMB.TECH: A small bit beat but not the full story / Corbion: Dividend sweetener / CTP: Q4 results lighter due to some delays; stronger 2026 outlook / DEME: Strong FY25 numbers and FY26 outlook / Elia Group: Preview FY25 results / SBM Offshore: Another step-up in shareholder return / Syensqo: Substantial miss in 4Q25; FY26 outlo...

Wim Hoste
  • Wim Hoste

Corbion FIRST LOOK: FY25 EBITDA +27% organ., FY26 margin guidance of 1...

FY25 adj EBITDA increased by 27% organically and was close to our and consensus forecasts. FY26 guidance of a c. 100bps adj EBITDA margin improvement to around 17% is no surprise (KBCS 16.7%, CSS 16.9%). We remind that Corbion is conducting a strategic review on PLA which we believe will most likely result in an exit of Corbion, while still remaining the lactic acid supplier to the buyer. Biochemicals will be de-emphasized, which will put the growth focus on food preservation and formulation, al...

Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Mathijs Geerts Danau
  • Wim Hoste
  • Wim Lewi

Morning Notes : ARGX BB, BEKB BB, CRBN NA, CMBT BB, SEQUA BB, SOF BB, ...

: ARGX BB, BEKB BB, CRBN NA, CMBT BB, SEQUA BB, SOF BB, UCB BB, SHUR BB, CTPNV NA, DEME BB, SYENS BB

 PRESS RELEASE

Corbion announces strong full-year 2025 results with +26.7% organic Ad...

Corbion announces strong full-year 2025 results with +26.7% organic Adjusted EBITDA growth, +63.3% EPS growth, and €90.8 million in FCF; announces special dividend Corbion, the Amsterdam-listed sustainable food-ingredients company that champions preservation through application of science, today publishes its results for the year ending 31 December 2025. Key highlights annual results 2025:   Organic sales growth: +2.2%  (Q4: +5.4%)  Volume/mix: +3.4%  (Q4: +8.8%)  Price:           -1.2%  (Q4: -3.4%)  Sales: € 1,267.4 million  (Q4: € 310.2 million)  Adjusted EBITDA: € 204.3 million    (Q...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ageas: Upgrading net op. result FY26 target to >€1.5bn from €1.35bn in FY25 as M&A starts contributing / CFE: Strong 2H, flips to net cash and outlook better / Deceuninck: FY25 results in line with expectations, Türkiye a tad better / GBL: Exits Umicore fully / Vopak: Five-year SBB programme announced / Wolters Kluwer: 2025 roughly in line, good 2026 outlook

Kristof Samoy ... (+4)
  • Kristof Samoy
  • Livio Luyten
  • Thomas Couvreur
  • Wim Hoste
Wim Hoste
  • Wim Hoste

Deceuninck FIRST LOOK: Slight beat in FY25 adj EBITDA, no precise FY26...

Deceuninck reported a 6.7% drop in FY25 adj EBITDA to € 110.2m, which was 4% above our estimate and 2% above consensus. Deceuninck is not offering a precise guidance for FY26, but mentioned that the market shows some signs of stabilization, although it is too early to predict when a meaningful recovery of demand will materialize. The search for a new CEO is ongoing. While acknowledging the cyclical character of Deceuninck's business, we believe valuation is clearly attractive and we reiterate ou...

 PRESS RELEASE

Ageas reports full-year 2025 results

Ageas reports full-year 2025 results Regulated information • Brussels, 25 February 2026 • 7:30am (CET) Ageas reports full-year 2025 results Strong performance in a transformational year for Ageas INFLOWS NETOPERATINGRESULT HOLDING FREE CASH FLOW GROSS DIVIDEND 2025EUR 19.6 billion EUR 1.65 billion EUR 774 million EUR 3.75+9% vs 2024 +33% vs 2024 +19% vs 2024 +7% vs 2024 A complete overview of the figures and comparison with previous year can be found on page 7 of this press release and on the Ageas website. Hans De Cuyper, CEO Ageas, comments: “2025 was a landmark year for Ageas - a yea...

 PRESS RELEASE

Ageas rapporteert resultaten over 2025

Ageas rapporteert resultaten over 2025 Gereglementeerde informatie • Brussel, 25 februari 2026 • 7u30 (CET) Ageas rapporteert resultaten over 2025Sterke resultaten in een jaar van transformatie voor Ageas PREMIE-INKOMEN NETTOOPERATIONEELRESULTAAT HOLDING FREE CASH FLOW BRUTO DIVIDEND 2025EUR 19,6 miljard EUR 1,65 miljard EUR 774 miljoen EUR 3,75+9% vs 2024 +33% vs 2024 +19% vs 2024 +7% vs 2024 Een overzicht van de cijfers en een vergelijking met vorig jaar is te vinden op pagina 8 van dit persbericht en op de website van Ageas. Hans De Cuyper, CEO Ageas, zei: “2025 was een mijlpaal voor A...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch